Healthcare Industry News: Royal Philips
News Release - September 12, 2006
CellPoint Adds Former Chief Medical Officer of Philips Medical Systems, F. David Rollo, M.D., Ph.D., as PresidentCENTENNIAL, Colo.--(HSMN NewsFeed)--Sept. 12, 2006--CellPoint today announced that F. David Rollo, M.D., Ph.D., has joined the company as President. Dr. Rollo was formerly Chief Medical Officer of Philips Medical Systems, a global leader in diagnostic imaging systems and healthcare information technology solutions.
CellPoint has licensed five radiopharmaceutical technology platforms from The University of Texas M.D. Anderson Cancer Center. The company plans to apply for FDA approval of its first universal oncology molecular imaging agent, 99m-Tc-EC-DG (Technetium-99m-ethylenedicysteine-deoxyglucose), in 2007. 99m-Tc-EC-DG is the first oncology imaging agent designed to image certain cancers and cardiovascular diseases on existing SPECT (Single Photon Emission Computed Tomography) "gamma" cameras, found in over 98 percent of hospitals in the United States and the majority of hospitals throughout the world. As President, Dr. Rollo will lead the implementation of CellPoint's business strategy and operating plan, including the completion of the 99m-Tc-EC-DG trial. Philips Medical Systems has been collaborating with CellPoint on the 99m-Tc-EC-DG oncology trial. (Editor's Note: Please see http://www.medical.philips.com/main/news/content/file_426.html.)
The company plans to begin clinical trials on its first oncology intracellular therapeutic, 188-Re/Cold Re-EC-DG (Rhenium-188/Cold Rhenium-ethylenedicysteine-deoxyglucose). Dr. Rollo will direct the company in the conduct of the therapeutic trial and the next seven radiodiagnostic and therapeutic trials slated for 2007.
A cardiologist by training, Dr. Rollo brings CellPoint more than 38 years of applicable corporate, clinical and academic experience. Most recently at Philips Medical Systems, a division of Royal Philips, Rollo supported the chief technology officer's office in developing and implementing a worldwide medical application strategy for Philips Medical Systems as a healthcare delivery company.
Before Philips, Dr. Rollo served as Senior Vice President for Medical Affairs and Executive Medical Director for Raytel Medical Corporation (1996-1999), Chairman and CEO of Metricor (a former subsidiary of Humana, 1992-1996), Chief Medical Officer and Senior Vice President - Medical Affairs for Humana Corporation (1980-1992), and various clinical and academic appointments at Vanderbilt University Medical Center (Nashville, TN), University of California San Francisco (San Francisco), Johns Hopkins University (Baltimore), and Upstate Medical Center (Syracuse, NY). Of note, during his tenure at Humana, Dr. Rollo was the technology and clinical due-diligence advisor for medically related capital investments made by a collaborative investment partnership involving Humana, Hambrecht & Quist and Warburg Pincus.
Dr. Rollo has co-edited eight textbooks, published over 270 articles and given more than 300 presentations. In addition, he has received nearly 60 awards, honors and grants and has held more than 40 professional appointments and 60 committee memberships. Lastly, while with Humana, Dr. Rollo created the original Centers of Excellence program which brought together renowned physicians and technical staff to produce regional, national and international magnet clinical services in more than a dozen medical specialties. This program created 39 Centers of Excellence (12 of which were Cardiovascular Centers of Excellence) including Humana Heart International, Arizona Heart Institute and the renowned Heart Institute at Wellington Hospital in London.
CellPoint, with headquarters in Centennial, Colo., is a privately held biotechnology company developing radioactive drugs (radiopharmaceuticals) for diagnosing and treating cancer, and diagnosing heart disease. CellPoint has exclusive license to five drug-development technology platforms, all from The University of Texas M.D. Anderson Cancer Center in Houston, a recognized world leader in cancer research and clinical care. Information on CellPoint's products, recent press releases and patent filings can be obtained through its website at http://www.cellpointweb.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.